Integrating Artifcial Intelligence with Quality by Design in the Formulation of Lecithin/Chitosan Nanoparticles of a Poorly Water‑Soluble Drug

dc.AffiliationOctober university for modern sciences and Arts MSA
dc.contributor.author Dawoud, Marwa H. S
dc.contributor.authorMannaa, Islam S
dc.contributor.authorAbdel‑Daim, Amira 
dc.contributor.authorSweed, Nabila M
dc.date.accessioned2023-08-13T08:29:18Z
dc.date.available2023-08-13T08:29:18Z
dc.date.issued2023-08
dc.description.abstractThe aim of the current study is to explore the potential of artifcial intelligence (AI) when integrated with Quality by Design (QbD) approach in the formulation of a poorly water-soluble drug, for its potential use in carcinoma. Silymarin is used as a model drug for its potential efectiveness in liver cancer. A detailed QbD approach was applied. The efect of the critical process parameters was studied on each of the particle size, size distribution, and entrapment efciency. Response surface designs were applied in the screening and optimization of lecithin/chitosan nanoparticles, to obtain an optimized formula. The release rate was tested, where artifcial neural network models were used to predict the % release of the drug from the optimized formula at diferent time intervals. The optimized formula was tested for its cytotoxicity. A design space was established, with an optimized formula having a molar ratio of 18.33:1 lecithin:chitosan and 38.35 mg silymarin. This resulted in nanoparticles with a size of 161 nm, a polydispersity index of 0.2, and an entrapment efciency of 97%. The optimized formula showed a zeta potential of +38 mV, with well-developed spherical particles. AI successfully showed high predic- tion ability of the drug’s release rate. The optimized formula showed an enhancement in the cytotoxic efect of silymarin with a decreased IC50 compared to standard silymarin. Lecithin/chitosan nanoparticles were successfully formulated, with deep process and product understanding. Several tools were used as AI which could shift pharmaceutical formulations from experience-dependent studies to data-driven methodologies in the future.en_US
dc.description.urihttps://www.scimagojr.com/journalsearch.php?q=19374&tip=sid&clean=0
dc.identifier.doihttps://doi.org/10.1208/s12249-023-02609-5
dc.identifier.otherhttps://doi.org/10.1208/s12249-023-02609-5
dc.identifier.urihttp://repository.msa.edu.eg/xmlui/handle/123456789/5676
dc.language.isoenen_US
dc.publisherSpringer International Publishing AGen_US
dc.relation.ispartofseriesAAPS PharmSciTech;(2023) 24:169
dc.subjectartifcial neural network en_US
dc.subjectdeep learning en_US
dc.subjecthepatocellular carcinoma en_US
dc.subjectIshikawa diagram en_US
dc.subjectlecithin chitosan nanoparticles en_US
dc.subjectquality by design en_US
dc.subjectresponse surface designen_US
dc.titleIntegrating Artifcial Intelligence with Quality by Design in the Formulation of Lecithin/Chitosan Nanoparticles of a Poorly Water‑Soluble Drugen_US
dc.typeArticleen_US

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
s12249-023-02609-5.pdf
Size:
1.75 MB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
51 B
Format:
Item-specific license agreed upon to submission
Description: